References
- Vandamme AM, Camacho RJ, Ceccherini-Silberstein F, de Luca A, Palmisano L, Paraskevis D, . European HIV Drug Resistance Guidelines Panel. European recommendations for the clinical use of HIV drug resistance testing: 2011 update. AIDS Rev. 2011;13(2):77–108.
- Shafer RW, Rhee SY, Pillay D, Miller V, Sandstrom P, Schapiro JM, . HIV-1 protease and reverse transcriptase mutations for drug resistance surveillance. AIDS. 2007;21(2):215–23.
- Bennett DE, Camacho RJ, Otelea D, Kuritzkes DR, Fleury H, Kiuchi M, . Drug resistance mutations for surveillance of transmitted HIV-1 drug-resistance: 2009 update. PLoS ONE. 2009;4(3):e4724.
- Daar ES. Emerging resistance profiles of newly approved antiretroviral drugs. Top HIV Med. 2008;16(4):110–6.
- Buckton AJ, Harris RJ, Pillay D, Cane PA. HIV type-1 drug resistance in treatment-naive patients monitored using minority species assays: a systematic review and meta-analysis. Antivir Ther. 2011;16(1):9–16.
- Pillay D. Current patterns in the epidemiology of primary HIV drug resistance in North America and Europe. Antivir Ther. 2004;9(5):695–702.
- van Vaerenbergh K, Debaisieux L, de Cabooter N, Declercq C, Desmet K, Fransen K, . Prevalence of genotypic resistance among antiretroviral drug-naive HIV-1-infected patients in Belgium. Antivir Ther. 2001;6(1):63–70.
- Derdelinckx I, van Laethem K, Maes B, Schrooten Y, de Wit S, Florence E, . Current levels of drug resistance among therapy-naive HIV-infected patients have significant impact on treatment response. J Acquir Immune Defic Syndr. 2004;37(5):1664–6.
- Vercauteren J, Derdelinckx I, Sasse A, Bogaert M, Ceunen H, de Roo A, . Prevalence and epidemiology of HIV type 1 drug resistance among newly diagnosed therapy-naive patients in Belgium from 2003 to 2006. AIDS Res Hum Retroviruses. 2008;24(3):355–62.
- van Beckhoven D, Buvé A, Ruelle J, Seyler L, Sasse A; Belgian HIV Cohort Study Group. A national cohort of HIV-infected patients in Belgium: design and main characteristics. Acta Clin Belg. 2012;67(5):333–7.
- de Oliveira T, Deforche K, Cassol S, Salminen M, Paraskevis D, Seebregts C, . An automated genotyping system for analysis of HIV-1 and other microbial sequences. Bioinformatics. 2005;21(19):3797–800.
- HIV Drug Resistance Database. The World Health Organization 2009 List of Mutations for Surveillance of Transmitted Drug Resistant HIV strains. Sandford (CA): Standford University; 2013. Available from: http://hivdb.stanford.edu/pages/WHOResistanceList.html. Accessed 5/11/2013.
- HIV Drug Resistance Database. HIVdbP program: genotypic resistance interpretation Algorithm. Sandford (CA): Standford University; 2013. Available from: http://sierra2.stanford.edu/sierra/servlet/JSierra. Accessed 5/11/2013.
- European AIDS Clinical Society (EACS). EACS guidelines. Paris: EACS; 2013. Available from: http://www.eacsociety.org/Guidelines.aspx Accessed 5/11/2013.
- Chalmet K, Staelens D, Blot S, Dinakis S, Pelgrom J, Plum J, . Epidemiological study of phylogenetic transmission clusters in a local HIV-1 epidemic reveals distinct differences between subtype B and non-B infections. BMC Infect Dis. 2010;10:262.
- Wittkop L, Günthard HF, de Wolf F, Dunn D, Cozzi-Lepri A, de Luca A, . EuroCoord-CHAIN Study Group. Effect of transmitted drug resistance on virological and immunological response to initial combination antiretroviral therapy for HIV (EuroCoord-CHAIN joint project): a European multicohort study. Lancet Infect Dis. 2011;11(5):363–71.